benign%20prostatic%20hyperplasia
BENIGN PROSTATIC HYPERPLASIA
Benign prostatic hyperplasia (BPH) is a histopathological diagnosis characterized by epithelial cell & smooth muscle cell proliferation in the transition zone of the prostate leading to a non-malignant enlargement of the gland, which may result in lower urinary tract symptoms, including voiding and storage symptoms.
It is commonly called enlarged prostate.
Etiology is unknown but due to its similarity to the embryonic morphogenesis of the prostate has led to the hypothesis that BPH may be the result of "reawakening" in adulthood of embryonic induction processes.

Introduction

  • Histopathological diagnosis characterized by epithelial cell & smooth muscle proliferation in the transition zone of the prostate leading to a non-malignant enlargement of the gland, w/c may result in lower urinary tract symptoms, including voiding & storage symptoms
  • Common disease of aging men
  • Two phases where prostate doubles its size:
    • At puberty
    • 25 yr old & beyond

Etiology

  • The exact cause of benign prostatic hyperplasia (BPH) is still not well understood

Signs and Symptoms

  • Dribbling at the end of urination
  • Nocturia
  • Pain after ejaculation or urination
  • Weak or interrupted urine stream
  • Trouble starting a urine stream
  • Urinary frequency
  • Urinary urgency
  • Urinary retention
  • Urinary incontinence
  • Urine w/ unusual smell or color

Risk Factors

  • Age 40 years old & older
  • Family history of benign prostatic hyperplasia (BPH)
  • Medical conditions such as obesity, heart & circulatory disease, type 2 diabetes mellitus (DM)
  • Lack of physical exercise
Editor's Recommendations
Most Read Articles
13 Jul 2017

According to the Singapore National Registry of Diseases Office (NRDO), prostate cancer is the third most common cancer and the sixth most common cause of cancer-related deaths affecting men in Singapore. Dr Daniel Tan, radiation oncologist and medical director of Asian American Radiation Oncology at Gleneagles Hospital, Singapore, speaks to Roshini Claire Anthony on the importance of early detection of prostate cancer and the challenges associated with diagnosing and treating this condition. 

15 Oct 2017
Physiotherapy and behaviour therapy appear to be effective interventions in females with overactive bladder syndrome, with those who have had no previous exposure to the treatments benefitting from post-therapy effects, a recent study has shown.
Christina Lau, 20 Jan 2016
New data from the phase III METEOR trial (Metastatic Renal Cell Carcinoma Phase III Study Evaluating Cabozantinib vs Everolimus) provide compelling evidence for the efficacy of cabozantinib in patients with advanced clear-cell renal cell carcinoma (RCC) who progressed after first-line VEGF receptor-tyrosine kinase inhibitor (TKI) therapy.
22 May 2015
A highly selective M3 antagonist developed for treating overactive bladder (OAB).